Charles Lapp: Difference between revisions
Notjusttired (talk | contribs) (fix ref, retirement info) |
Notjusttired (talk | contribs) m (Text replacement - " \| ?last(.*)\=(.*)( *)\| ?first(.*)\=(.*)( *)\| ?author" to " |last$1=$2 |first$3$4 |author") |
||
Line 90: | Line 90: | ||
==References== | ==References== | ||
<references> | <references> | ||
<ref name="Jason, Dec2009">{{Citation | <ref name="Jason, Dec2009">{{Citation |last1 = Jason |first 1 |authorlink1 = Leonard Jason |last2 = Porter |first 2 |authorlink2 = Nicole Porter |last3 = Shelleby |first 3 |authorlink3 = |last4 = Till |first 4 |authorlink4 = |last5 = Bell |first 5 |authorlink5 = David Bell |last6 = Lapp |first 6 |authorlink6 = Charles Lapp |last7 = Rowe |first 7 |authorlink7 = Kathy Rowe |last8 = De Meirleir |first 8 |authorlink8 = Kenny De Meirleir | ||
| last1 = Jason | |||
| last2 = Porter | |||
| last3 = Shelleby | |||
| last4 = Till | |||
| last5 = Bell | |||
| last6 = Lapp | |||
| last7 = Rowe | |||
| last8 = De Meirleir | |||
| title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS | | title = Severe versus Moderate criteria for the new pediatric case definition for ME/CFS | ||
| journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20 | | journal = Child Psychiatry and Human Development | volume = 40 | issue = 4 | page = 609-20 | ||
Line 106: | Line 98: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="JasonL2006paed">{{citation | <ref name="JasonL2006paed">{{citation |last1 = Jason |first 1 |authorlink1 = Leonard Jason |last2 = Jordan |first 2 |authorlink2 = Karen Jordan |last3 = Miike |first 3 |authorlink3 = Teruhisa Miike |last4 = Bell |first 4 |authorlink4 = David Bell |last5 = Lapp |first 5 |authorlink5 = Charles Lapp | ||
| last1 = Jason | | last6 = Torres-Harding | first6 = Susan | authorlink6 = Susan Torres-Harding |last7 = Rowe |first 7 |authorlink7 = Kathy Rowe |last8 = Gurwitt |first 8 |authorlink8 = Alan Gurwitt |last9 = De Meirleir |first 9 |authorlink9 = Kenny de Meirleir |last10 = Van Hoof |first 10 |authorlink10= Elke Van Hoof | ||
| last2 = Jordan | |||
| last3 = Miike | |||
| last4 = Bell | |||
| last5 = Lapp | |||
| last6 = Torres-Harding | first6 = Susan | authorlink6 = Susan Torres-Harding | |||
| last7 = Rowe | |||
| last8 = Gurwitt | |||
| last9 = De Meirleir | |||
| last10 = Van Hoof | |||
| title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome | | title = A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome | ||
| journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44 | | journal = Journal of Chronic Fatigue Syndrome | volume = 13 | issue = 2-3 | page = 1-44 | ||
Line 123: | Line 106: | ||
| url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf | | url = https://solvecfs.org/wp-content/uploads/2013/06/pediatriccasedefinitionshort.pdf | ||
}}</ref> | }}</ref> | ||
<ref name="Strayer, 2012">{{Citation | <ref name="Strayer, 2012">{{Citation |last1 = Strayer |first 1 |authorlink1 = David Strayer |last2 = Carter |first 2 |authorlink2 = William Carter |last3 = Stouch |first 3 |authorlink3 = |last4 = Stevens |first 4 |authorlink4 = Staci Stevens |last5 = Bateman |first 5 |authorlink5 = Lucinda Bateman |last6 = Cimoch |first 6 |authorlink6 = |last7 = Lapp |first 7 |authorlink7 = Charles Lapp |last8 = Peterson |first 8 |authorlink8 = Daniel Peterson | ||
| last1 = Strayer | | last9 = Chronic Fatigue Syndrome AMP-516 Study Group | authorlink9 = |last10 = Mitchell |first 10 |authorlink10 = William Mitchell | ||
| last2 = Carter | |||
| last3 = Stouch | |||
| last4 = Stevens | |||
| last5 = Bateman | |||
| last6 = Cimoch | |||
| last7 = Lapp | |||
| last8 = Peterson | |||
| last9 = Chronic Fatigue Syndrome AMP-516 Study Group | authorlink9 = | |||
| last10 = Mitchell | |||
| title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. | | title = A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. | ||
| journal = PLoS One | volume = 7 | issue = 3 | page = e31334 | | journal = PLoS One | volume = 7 | issue = 3 | page = e31334 | ||
Line 143: | Line 117: | ||
<ref name="Unger, 2017">{{Citation | <ref name="Unger, 2017">{{Citation | ||
| last1 = Unger | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger | | last1 = Unger | first1 = Elizabeth R. | authorlink1 = Elizabeth Unger | ||
| last2 = Lin | first2 = Jin-Mann S. | authorlink2 = Jin-Mann Sally Lin | | last2 = Lin | first2 = Jin-Mann S. | authorlink2 = Jin-Mann Sally Lin |last3 = Tian |first 3 |authorlink3 = | ||
| last3 = Tian | | last4 = Natelson | first4 = Benjamin H. | authorlink4 = Benjamin Natelson |last5 = Lange |first 5 |authorlink5 = Gudrun Lange |last6 = Vu |first 6 |authorlink6 = |last7 = Blate |first 7 |authorlink7 = |last8 = Klimas |first 8 |authorlink8 = Nancy Klimas | ||
| last4 = Natelson | first4 = Benjamin H. | authorlink4 = Benjamin Natelson | | last9 = Balbin | first9 = Elizabeth G. | authorlink9 = |last10 = Bateman |first 10 |authorlink10 = Lucinda Bateman |last11 = Allen |first 11 |authorlink11 = | ||
| last5 = Lange | | last12 = Lapp | first12 = Charles W. | authorlink12 = Charles Lapp |last13 = Springs |first 13 |authorlink13 = | ||
| last6 = Vu | |||
| last7 = Blate | |||
| last8 = Klimas | |||
| last9 = Balbin | first9 = Elizabeth G. | authorlink9 = | |||
| last10 = Bateman | |||
| last11 = Allen | |||
| last12 = Lapp | first12 = Charles W. | authorlink12 = Charles Lapp | |||
| last13 = Springs | |||
| last14 = Kogelnik | first14 = Andreas M. | authorlink14 = Andreas Kogelnik | | last14 = Kogelnik | first14 = Andreas M. | authorlink14 = Andreas Kogelnik | ||
| last15 = Phan | first15 = Catrina C. | authorlink15 = | | last15 = Phan | first15 = Catrina C. | authorlink15 = |last16 = Danver |first 16 |authorlink16 = | ||
| last16 = Danver | |||
| last17 = Podell | first17 = Richard N. | authorlink17 = Richard Podell | | last17 = Podell | first17 = Richard N. | authorlink17 = Richard Podell | ||
| last18 = Fitzpatrick | first18 = Trisha | authorlink18 = | | last18 = Fitzpatrick | first18 = Trisha | authorlink18 = | ||
Line 171: | Line 136: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Van Hoof, 2007">{{Citation | <ref name="Van Hoof, 2007">{{Citation |last1 = Van Hoof |first 1 |authorlink1 = Elke Van Hoof |last2 = De Becker |first 2 |authorlink2 = Pascale De Becker |last3 = Lapp |first 3 |authorlink3 = Charles Lapp |last4 = Cluydts |first 4 |authorlink4 = |last5 = De Meirleir |first 5 |authorlink5 = Kenny de Meirleir | ||
| last1 = Van Hoof | |||
| last2 = De Becker | |||
| last3 = Lapp | |||
| last4 = Cluydts | |||
| last5 = De Meirleir | |||
| title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome | | title = Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome | ||
| journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84 | | journal = The American Journal of the Medical Sciences | volume = 333 | issue = 2 | page = 78-84 | ||
Line 184: | Line 144: | ||
}} | }} | ||
</ref> | </ref> | ||
<ref name="Vojdani, 1998">{{Citation | <ref name="Vojdani, 1998">{{Citation |last1 = Vojdani |first 1 |authorlink1 = |last2 = Choppa |first 2 |authorlink2 = |last3 = Lapp |first 3 |authorlink3 = Charles Lapp | ||
| last1 = Vojdani | |||
| last2 = Choppa | |||
| last3 = Lapp | |||
| title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome | | title = Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome | ||
| journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16 | | journal = J Clin Lab Immunol | volume = 50 | issue = 1 | page = 1-16 |
Revision as of 04:56, May 11, 2022
Charles W. Lapp, MD, is a retired Internal Medicine physician and the Medical Director Emeritus at Hunter-Hopkins Center in Charlotte, North Carolina, US, which has a practice specializing in ME/CFS, fibromyalgia, and related conditions.[1] Earlier in his career, he practiced family medicine and pediatrics in Raleigh, NC.[2] He became interested in ME/CFS following an outbreak of three small epidemics of a chronic fatiguing illness in the Raleigh area. One of these outbreaks was among all the members of the N.C. Symphony Orchestra.[3]
From 1992 to 1995 Dr. Lapp acted as Medical Director of the Cheney Clinic in Charlotte, in collaboration with Dr. Paul Cheney. In August 1995, Dr. Lapp opened the Hunter-Hopkins Center in Charlotte, North Carolina where he practiced until his retirement in 2018.[2] His center does testing for disability insurance such as the two-day cardiopulmonary exercise test (2-day CPET) and a computer-assisted cognitive function test.
Following Dr. Lapp's retirement in 2018, the Hunter-Hopkins Center director became Dr. Vincent F. Hillman with Dr. Laura Black continuing on staff.[2]
Dr. Lapp serves on the editorial board of the journal, Fatigue: Biomedicine, Health & Behavior, published on behalf of the IACFS/ME.[4]
Awards[edit | edit source]
- 2009, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.[5]
IOM Committee on Diagnostic Criteria for ME/CFS[edit | edit source]
Dr Lapp was a reviewer for the 2015 report produced by the Institute of Medicine's Committee on Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.[6]
Pediatric Case Definition[edit | edit source]
- 2006, A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome[7] (Full Text)
Clinical Trials[edit | edit source]
The Hunter-Hopkins Center was one of two clinical sites participating in the Hemispherx Biopharma 511/open label Ampligen trials to gain FDA approval, which was ultimately unsuccessful. The Ampligen phase III trial results were published in 2012.[8][9] Ampligen, a brand name for Rintatolimod, is an IV medication, and was given twice weekly at the Hunter-Hopkins infusion room during the trial. The Hunter-Hopkins Center is currently one of four clinics that can administer Ampligen in the US.[9]
Clinic location[edit | edit source]
Dr Lapp retired in 2018, other physicians with expertise in ME/CFS can be contacted at the clinic he founded.
- Hunter-Hopkins Center
- 7421 Carmel Executive Park Dr.
- Charlotte, North Carolina 28226
- Telephone: (704) 543-9692
- Email: drlapp@drlapp.net
Notable studies[edit | edit source]
- 1997, Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach[10]
- 1998, Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome.[11]
- 1999, The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure[12]
- 2006, Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach[13]
- 2007, Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome[14] (Abstract)
- 2009, Severe versus Moderate criteria for the new pediatric case definition for ME/CFS[15] (Abstract)
- 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome[8] (Full Text)
- 2014, No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank[16] (Full Text)
- 2016, CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education. Morbidity and Mortality Weekly Report[17] - (Full Text)
- 2017, Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study[18] (Full Text)
- 2019, Initiating care of a patient with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)[19] (Full text)
- 2019, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning[20] (Full text)
Talks and interviews[edit | edit source]
- Dr. Lapp’s recommendations on supplements[21]
- 16 Feb 2016, CDC Grand Rounds - Chronic Fatigue Syndrome: Advancing Research and Clinical Education with Charles Lapp, MD, Elizabeth Unger, PhD, MD, Anthony Komaroff, MD and Avindra Nath, MD
HHS/CFSAC Testimony[edit | edit source]
Open Letter to The Lancet[edit | edit source]
Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Lapp, along with 42 colleagues in the ME/CFS field, signed the second letter.[22] In 2018, Dr. Lapp, with more than 100 colleagues in the ME/CFS field, signed the third letter.[23]
- 10 February 2016, An open letter to The Lancet, again - Virology blog
- 18 June 2018, Trial By Error: An Open Letter to The Lancet, Two Years On
Online presence[edit | edit source]
Learn more[edit | edit source]
- 2012, What Are The Most Important Things To Remember About CFS/FM?
- Curriculum Vitae - Charles W. Lapp, MD
- 2018, An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview[24]
See also[edit | edit source]
- Hunter-Hopkins Center
- NIH Post-Infectious ME/CFS Study
- Ampligen
- 1984 Chapel Hill outbreak
- Dr Vincent F. Hillman
- Dr Laura Black
References[edit | edit source]
- ↑ "Curriculum Vitae – Charles W. Lapp, MD". Hunter-Hopkins Center. Retrieved October 26, 2020.
- ↑ 2.0 2.1 2.2 Lapp, Charles (February 12, 2018). "Dr. Lapp Retires and Dr. Vincent Hillman Takes the Helm". Hunter-Hopkins Center. Retrieved December 23, 2018.
- ↑ Garloch, Karen (2009). "Cause of illness remains unknown". NewsOK.
- ↑ "Fatigue: Biomedicine, Health & Behavior". www.tandfonline.com. Retrieved November 1, 2019.
- ↑ "IACFS/ME Awardees". IACFS/ME. Retrieved April 23, 2020.
- ↑ Institute of Medicine. "ME/CFS Presentation" (PDF). National Academies Press. Retrieved December 23, 2018.
- ↑ 1first 2 first 1 first 3 first 2, "A Pediatric Case Definition for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome"
- ↑ 8.0 8.1 1first 2 first 1 first 3 first 2, "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome."
- ↑ 9.0 9.1 Hunter-Hopkins Center. "Ampligen | Research | Hunter-Hopkins Center, P.A." Retrieved December 23, 2018.
- ↑ Charles W. Lapp. (1997). Management of Chronic Fatigue Syndrome in Children: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 3, Iss. 2, pp 59-76. http://dx.doi.org/10.1300/J092v03n02_07
- ↑ 1first 2 first 1 first 3 first 2, "Downregulation of RNase L inhibitor correlates with upregulation of interferon-induced proteins (2-5A synthetase and RNase L) in patients with chronic fatigue immune dysfunction syndrome"
- ↑ Aristo Vojdani & Charles W. Lapp. (1999). The Relationship Between Chronic Fatigue Syndrome and Chemical Exposure. Journal of Chronic Fatigue Syndrome, Vol. 5, Iss. 3-4, pp. 207-221. http://dx.doi.org/10.1300/J092v05n03_18
- ↑ Charles W. Lapp. (2006). Recognizing Pediatric CFS in the Primary Care Practice: A Practicing Clinician's Approach. Journal of Chronic Fatigue Syndrome, Vol. 13, Iss. 2-3, pp. 89-96. http://dx.doi.org/10.1300/J092v13n02_06
- ↑ 1first 2 first 1 first 3 first 2, "Defining the Occurrence and Influence of Alpha-Delta Sleep in Chronic Fatigue Syndrome"
- ↑ 1first 2 first 1 first 3 first 2, "Severe versus Moderate criteria for the new pediatric case definition for ME/CFS"
- ↑ Irlbeck, David M.; Vernon, Suzanne D.; McCleary, K. Kimberly; Bateman, Lucinda; Klimas, Nancy G.; Lapp, Charles W.; Peterson, Daniel L.; Brown, James R.; Remlinger, Katja S.; Wilfret, David A.; Gerondelis, Peter (2014). "No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank". BMC Research Notes. 7: 461. doi:10.1186/1756-0500-7-461.
- ↑ Unger, ER; Lin, JS; Brimmer, DJ; Lapp, CW; Komaroff, AL; Nath, A; Laird, S; Iskander, J (2016). "CDC Grand Rounds: Chronic Fatigue Syndrome — Advancing Research and Clinical Education". Morbidity and Mortality Weekly Report. 65 (5051): 1434–1438. doi:10.15585/mmwr.mm655051a4. -
- ↑ 3first 5 first 3 first 6 first 5, "Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study."
- ↑ Lapp, Charles W. (January 2019). "Initiating Care Of A Patient With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS)". Frontiers in Pediatrics. doi:10.3389/fped.2018.00415.
- ↑ Proskauer, Charmian; Rowe, Peter C.; Lapp, Charles W.; DeMaria, Alfred Jr; Bateman, Lucinda; Attewell, John R.; Proskauer, Daniel; Kiernicki, David J.; Adebayo, Seyi (2019). "Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning". Frontiers in Pediatrics. 6. doi:10.3389/fped.2018.00412. ISSN 2296-2360. PMID 30671425.
- ↑ Campbell, Bruce. "Dr Lapp's Recommendations on Supplements | ME/CFS & Fibromyalgia Self-Help". www.cfidsselfhelp.org. Retrieved December 23, 2018.
- ↑ "Open Letter Lancet Again".
- ↑ "An Open Letter to The Lancet, Two Years On".
- ↑ Johnson, Cort (March 28, 2018). "An ME/CFS and FM Pioneer Says Good-bye: The Charles Lapp Interview". Health Rising. Retrieved December 23, 2018.